Trial Profile
A Phase II Pilot Study of Zoledronic Acid, Pravastatin, and Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lonafarnib (Primary) ; Pravastatin; Zoledronic acid
- Indications Progeria
- Focus Adverse reactions
- 17 Jun 2014 New trial record
- 20 Apr 2010
- 09 Jun 2009